Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Kazuaki, Enya"'
Publikováno v:
Clinical and experimental nephrology. 26(4)
Background Azilsartan is an angiotensin II receptor blocker indicated for the treatment of adult hypertension. A previous single-dose study suggested that azilsartan may also be a promising agent for paediatric hypertension. However, the long-term sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62143a8f8679a02580ba72de22fb3d58
https://pubmed.ncbi.nlm.nih.gov/35024975
https://pubmed.ncbi.nlm.nih.gov/35024975
Publikováno v:
Clinical and Experimental Nephrology. 26:359-359
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e155f23f36b32af535dae20889436d0
https://doi.org/10.1007/s10157-021-02176-8
https://doi.org/10.1007/s10157-021-02176-8
Publikováno v:
Advances in Therapy
Introduction Azilsartan is an angiotensin II receptor blocker indicated for the treatment of patients with hypertension. The efficacy and safety of azilsartan are established in adults, but have not been evaluated in pediatric patients, nor has its p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33a145d77d881f0ea4cc3aa44d4166d4
https://pubmed.ncbi.nlm.nih.gov/30027478
https://pubmed.ncbi.nlm.nih.gov/30027478
Publikováno v:
Obstetrical & Gynecological Survey. 74:406-407
OBJECTIVE:To investigate the noninferiority of relugolix compared with leuprorelin acetate in reducing heavy menstrual bleeding associated with uterine leiomyomas.METHODS:In a double-blind, double-dummy trial, premenopausal women with uterine leiomyo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05a315e4ab178196b706f686e8c6756a
https://doi.org/10.1097/01.ogx.0000568888.86662.e0
https://doi.org/10.1097/01.ogx.0000568888.86662.e0
Publikováno v:
Diabetes Technology & Therapeutics. 17:215-223
This study applied a pharmacodynamic model-based approach to evaluate the long-term durability and glycemic control of pioglitazone in comparison with other oral glucose-lowering drugs in Japanese type 2 diabetes mellitus (T2DM) patients.Japanese T2D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8fc17a81a6a8c9fe49a629bfceefcaf
https://doi.org/10.1089/dia.2014.0222
https://doi.org/10.1089/dia.2014.0222
Publikováno v:
Blood Pressure Monitoring
Morning blood pressure (BP) surge is reported as a risk factor for cardiovascular events and end-organ damage independent of the 24-h BP level. Controlling morning BP surge is therefore important to help prevent onset of cardiovascular disease. We co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40b8a9ce1213fe9d1bcb59ad87aa9315
https://doi.org/10.1097/mbp.0000000000000042
https://doi.org/10.1097/mbp.0000000000000042
Publikováno v:
Fertility and Sterility. 112:922-929.e2
Objective To investigate the efficacy and safety of the oral gonadotropin-releasing hormone receptor antagonist, relugolix, in patients experiencing uterine fibroid–associated pain. Design Phase 3, multicenter, randomized, double-blind, placebo-con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d643afbb470eb7d53e586a5f7bb76f8
https://doi.org/10.1016/j.fertnstert.2019.07.013
https://doi.org/10.1016/j.fertnstert.2019.07.013
Publikováno v:
Diabetes, obesitymetabolism. 18(9)
This multicentre, open-label, phase III study investigated the safety and efficacy of the G-protein-coupled receptor 40 agonist fasiglifam. Japanese patients with type 2 diabetes and inadequate glycaemic control despite diet and/or exercise (n = 282)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1ac9c3dd8daf5e5e5f3103f632d56d2
https://pubmed.ncbi.nlm.nih.gov/27178047
https://pubmed.ncbi.nlm.nih.gov/27178047
Publikováno v:
Blood pressure. 22
Abnormal variations in night-time hypertension such as "non-dipping" type (10% decrease in nocturnal systolic blood pressure [SBP] from daytime SBP) are a risk factor for cardiovascular events independent of 24-h BP.As part of a randomized, double-bl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2cad2c7a81f621241aa9a36c3aba7ea
https://pubmed.ncbi.nlm.nih.gov/23885792
https://pubmed.ncbi.nlm.nih.gov/23885792
Autor:
Hiromi, Rakugi, Kazuaki, Enya
Publikováno v:
Nihon rinsho. Japanese journal of clinical medicine. 70(9)
Azilsartan is a new ARB with the specific and potent angiotensin II receptor binding-inhibitory effect and more continuous angiotensin II antagonistic and antihypertensive actions in pre-clinical studies compared with other ARBs. The controlled clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6f231effe3f21f9adfb1f09008e63141
https://pubmed.ncbi.nlm.nih.gov/23012812
https://pubmed.ncbi.nlm.nih.gov/23012812